Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemoglobin subunit gamma-1 (HBG1) and Hemoglobin subunit gamma-2 (HBG2) are highly homologous protein subunits that, together with alpha-globin subunits, assemble to form fetal hemoglobin (HbF, a2g2). During fetal development, HbF serves as the primary oxygen carrier, possessing a higher affinity for oxygen than adult hemoglobin (HbA, a2b2) to facilitate oxygen transfer across the placenta. Shortly after birth, a developmental switch occurs where the expression of HBG1 and HBG2 is silenced by transcriptional repressors such as BCL11A and LRF/ZBTB7A, and adult beta-globin (HBB) expression is activated. In patients with beta-hemoglobinopathies, such as sickle cell disease (SCD) and beta-thalassemia, mutations in the HBB gene lead to defective adult hemoglobin, causing severe clinical manifestations like vaso-occlusive crises and chronic anemia.
HBG1 and HBG2 have emerged as major therapeutic targets, as inducing their expression to restore HbF levels can functionally compensate for defective beta-globin and prevent the polymerization of sickle hemoglobin. Therapeutic strategies include ex vivo gene editing of autologous hematopoietic stem cells (using CRISPR-Cas9, CRISPR-Cas12a, or base editors) to disrupt repressor binding sites in the HBG1/2 promoters, as seen with investigational therapies like renizgamglogene autogedtemcel, ristoglogene autogetemcel, and OTQ923. Additionally, pharmacological agents such as hydroxyurea, decitabine, and histone deacetylase (HDAC) inhibitors are utilized to epigenetically de-repress HBG1/2 expression and elevate HbF levels.
Reactivation of fetal hemoglobin (HbF) expression by disrupting transcriptional repressor binding sites (e.g., BCL11A) in the HBG1 and HBG2 promoters via ex vivo gene editing (CRISPR-Cas9, CRISPR-Cas12a, or base editing), or by pharmacological de-repression of the HBG1 and HBG2 promoters using small-molecule HbF inducers (such as DNMT inhibitors, HDAC inhibitors, E3 ligase modulators, or sGC activators).
12 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemoglobin subunit gamma-1 and Hemoglobin subunit gamma-2 (HBG1/HBG2).